{"id":8505,"date":"2016-11-18T10:20:28","date_gmt":"2016-11-18T09:20:28","guid":{"rendered":"https:\/\/news.embl.de\/?p=8505"},"modified":"2024-03-25T10:07:29","modified_gmt":"2024-03-25T09:07:29","slug":"1611-blueprint-advances-epigenetics","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/science\/1611-blueprint-advances-epigenetics\/","title":{"rendered":"BLUEPRINT project delivers"},"content":{"rendered":"

Blood disease research has been taken to a new level with a suite of 47 scientific papers published in Cell<\/em><\/a> and other high-profile journals by the International Human Epigenome Consortium (IHEC<\/a>). To support biomedical research, IHEC and the EU-funded BLUEPRINT project <\/a>have made the 1000+ associated datasets freely available to all.<\/p>\n

The work published today is the result of coordinated efforts by scientists in Canada, Japan, Singapore, South Korea, the United States, the United Kingdom, Germany and other EU Member States. EMBL-EBI provided data coordination, analysis and infrastructure, and contributed directly to research findings.<\/p>\n

Read our feature story:\u00a0Blood, Big Data and Epigenetics<\/a> on the EMBL-EBI website.<\/p>\n

\n

About BLUEPRINT<\/h3>\n

The project BLUEPRINT \u2013 A BLUEPRINT of Haematopoietic Epigenomes is a large-scale research project receiving close to 30 million euro funding from the EU. Forty-two leading European universities, research institutes and industry entrepreneurs participate in what is one of the two first \u2018high impact research initiatives\u2019 to receive funding from the EU. The 42 partner organisations represent 33 academic groups and 9 companies from 12 countries.<\/p>\n

Comprehensive sets of reference epigenome data relevant to health and disease are available freely through BLUEPRINT and the International Human Epigenome Consortium (IHEC).<\/p>\n